资料显示，济民健康管理股份有限公司位于浙江省台州市黄岩区北院路888号，成立日期1996年12月24 日，上市日期2015年2月17日，公司主营业务涉及医疗器械的研发、生产和销售,医疗服务,以及大输液产 品研发、生产和销售。主营业务收入构成为：医药制造52.07%，医疗服务46.01%，医药贸易1.54%，其 他(补充)0.38%。 截至9月30日，济民健康股东户数5.81万，较上期增加107.00%；人均流通股9035股，较上期减少 51.69%。2025年1月-9月，济民健康实现营业收入5.45亿元，同比减少20.21%；归母净利润-7715.04万 元，同比减少371.51%。 2月25日，济民健康涨1.68%，成交额7577.07万元。两融数据显示，当日济民健康获融资买入额400.17 万元，融资偿还379.04万元，融资净买入21.13万元。截至2月25日，济民健康融资融券余额合计1.69亿 元。 融资方面，济民健康当日融资买入400.17万元。当前融资余额1.69亿元，占流通市值的3.55%，融资余 额低于近一年20%分位水平，处于低位。 融券方面，济民健康2月25日融券偿还0.00股，融券卖出3 ...

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

Group 1 - The company has appointed Tianjian Accounting Firm as the auditor for its 2025 financial statements and internal control audits [1][2] - The signing auditors have changed due to internal adjustments at Tianjian, with Wang Chao replacing Peng Haowei [2] - Wang Chao has been engaged in auditing since 2017 and became a certified public accountant in April 2021 [3] Group 2 - Wang Chao has no criminal or administrative penalties in the past three years [4] - The new signing auditor meets the independence requirements as per the Code of Ethics for Chinese Certified Public Accountants [5] - The change in signing auditors will not affect the audit work for the company's 2025 financial statements and internal controls [6] Group 3 - The company has initiated a share repurchase program, with a total repurchase amount between RMB 100 million and RMB 200 million [9] - As of January 30, 2026, the company has repurchased 5,340,280 shares, accounting for 1.02% of the total share capital, with a total expenditure of approximately RMB 42.09 million [9][10] - In January 2026, the company repurchased 2,279,780 shares, representing 0.43% of the total share capital, with a total expenditure of approximately RMB 20.10 million [10]

Group 1 - The company Jimin Health announced a change in its signing registered accountants to Lai Xingkai and Wang Chao [2]

Summary of Key Points Core Viewpoint - Jimin Health (603222.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Group 1: Share Buyback Details - As of January 30, 2026, the company has repurchased a total of 5,340,280 shares, which represents 1.02% of the company's total share capital [1] - The highest purchase price for the shares was 9.75 yuan per share, while the lowest was 5.87 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees, is 42,085,552.3 yuan [1]

证券代码：603222 证券简称：济民健康 公告编号：2026-004 济民健康管理股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第 五届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司使用自有资金及金融机构借款以集中竞价交易方式回购公司股 份，回购价格不超过人民币 10 元/股（含）；回购资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）；回购期限为自董事会审议通过回 购方案之日起不超过 12 个月。具体内容详见公司于 2025 年 3 月 29 日在上海证券 交易所网站披露的《公司关于以集中竞价交易方式回购股份的预案》（公告编号： 2025-008）。 二、回购股份的进展情况 根据《上市公司回购股份规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，上市公司应当在回购股份占上市公司总股本的比 例每增加 1%的事实发生之日起 3 日内予以公告。现将公司回购股份进展情况公告 如下： 截至 2026 年 1 月 30 日，公司通过集中竞价交易方式累计回购股份 5,340,280 股，占公司 ...

济民健康管理股份有限公司 关于更换签字会计师的公告 证券代码：603222 证券简称：济民健康 公告编号：2026-005 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 济民健康管理股份有限公司（以下简称"公司"）分别于 2025 年 4 月 27 日、 2025 年 5 月 22 日召开第五届董事会第十八次会议、2024 年年度股东大会，审议 通过了《关于公司确认支付2024年度审计报酬及续聘2025年度审计机构的议案》， 同意公司聘任天健会计师事务所（特殊普通合伙）（以下简称"天健会计师事务 所"）为公司 2025 年度财务报表审计和内部控制审计的会计师事务所。具体内 容详见公司于 2025 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露 的《关于续聘会计师事务所的公告》（公告编号：2025-016）。 签字会计师王潮，2017 年开始从事上市公司审计，2021 年 4 月成为中国注 册会计师，2021 年 4 月开始在天健会计师事务所执业。 （二）诚信记录 王潮近三年内未曾因执业行为 ...

Core Viewpoint - Jimin Health (603222) expects a net loss of 210 million to 250 million yuan for 2025, which is an increase compared to the previous year's loss of 59.71 million yuan [1] Financial Performance - The company anticipates a non-recurring net loss of 205 million to 245 million yuan for 2025 [1] - The company has recognized an inventory impairment provision of approximately 37 million yuan for its pre-filled catheter flushing devices and safety syringes [1] Legal and Compliance Issues - Due to the case involving the forgery of company seals by He Qinghong and others, the company has confirmed related losses of approximately 38 million yuan [1] Asset Valuation - The performance of Ezhou Second Hospital is expected to decline in 2025, leading the company to recognize a goodwill impairment provision of approximately 20 million yuan [1] - After this provision, the cumulative impairment recognized will be approximately 136 million yuan, with a remaining book value of about 15.14 million yuan [1]

Core Viewpoint - Jimin Health (603222) expects a net profit loss of between 210 million to 250 million yuan for the fiscal year 2025, indicating an increase in losses compared to the previous year [1] Group 1: Financial Performance - The anticipated net profit loss for 2025 represents a worsening financial situation for the company compared to the same period last year [1] - The company attributes the increased losses to several factors, including the "He Qinghong stamp forging incident," which has further impacted revenue [1] Group 2: Contributing Factors - The financial performance is also affected by the provision for inventory impairment, recognition of losses related to implicated distributors, and the provision for goodwill impairment concerning Ezhou Second Hospital [1]

Core Viewpoint - Jimin Health has announced a projected net loss for the year 2025, indicating a significant increase in losses compared to the previous year [1] Financial Performance - The company expects a net profit attributable to shareholders of the parent company to be between -210 million and -250 million yuan for 2025, which is a deterioration from the previous year's loss of -59.71 million yuan [1] - The projected net profit, excluding non-recurring gains and losses, is anticipated to be between -205 million and -245 million yuan for 2025 [1]